

症 例 報 告

進行がん患者に対する黄連解毒湯の使用経験

小杉寿文*¹ 島川勇介*² 富田由紀子*² 山田康隆*²
三根奈々*² 久我公美子*² 鷗池直邦*¹

要旨：悪液質に代表されるがん患者特有の全身性炎症状態や、転移・浸潤による局所の炎症に対する清熱作用を期待して、黄連解毒湯をがん患者の症状緩和目的に使用している。2008年から2015年までの黄連解毒湯処方例を後方視的に検討した。全処方患者数57例のうち、がん患者は53例で、全例が転移や浸潤によって何らかの症状を呈した進行がんであった。肺がん14例、大腸がん7例、乳がんおよび腎がん6例、食道がん4例、胃がん3例その他9例であった。脳転移16例、脳腫瘍2例、椎体転移（脊髄浸潤含む）23例、肝転移6例などであった。鎮痛薬やステロイド、放射線治療などを併用している症例もあるが、明らかに黄連解毒湯の関与によって症状が緩和されていると考えられた症状は痛み15例（無効7例）、黄疸などの搔痒感6例（無効1例）、脳転移による眩暈・ふらつき5例（無効1例）、意識状態の改善3例であった。吐血、下血および喀血に処方した6例は再燃なく経過した。

索引用語：黄連解毒湯、緩和ケア、がん

PAIN AND KAMPO MEDICINE Vol.26 (2016)

Efficacy of orengedokuto for advanced cancer patient

Toshifumi KOSUGI*¹, Yusuke SHIMAKAWA*², Yukiko TOMITA*², Yasutaka YAMADA*², Nana MINE*², Kumiko KUGA*² and Naokuni UIKE*¹

Abstract: We use orengedokuto, which has a heat removing action, to relieve symptoms of systemic inflammatory conditions associated with cancer such as cachexia and local inflammation resulting from metastases and invasion. We retrospectively studied patients prescribed with orengedokuto between 2008 and 2015. Of a total of 57 patients prescribed with orengedokuto, 53 patients had cancer, all at an advanced stage, presenting with some kind of symptoms resulting from metastases or invasion. The cancer types were lung cancer in 14 patients, colorectal cancer in 7 patients, breast cancer in 6 patients, renal cancer in 6 patients, esophageal cancer in 4 patients, gastric cancer in 3 patients, and others in 9 patients. Sixteen patients had brain metastasis, 3 patients had brain tumor, 23 patients had vertebral body metastasis (including spinal infiltration), and 6 patients had liver metastasis. It was considered that the use of orengedokuto clearly improved the symptoms of pain in 15 patients (10 non-responders), itching sensation associated with jaundice, etc., in 6 patients (1 non-responder), dizziness and light-headedness associated with brain metastasis in 5 patients (1 non-responder), and the level of consciousness in 2 patients, albeit concurrent use of analgesic agents, steroids, and radiotherapy. No relapse occurred in the 6 patients who were prescribed orengedokuto for hematemesis, melena, and hemoptysis.

Key words: orengedokuto, palliative care, cancer

*¹ Saga-Ken Medical Centre Koseikan, Department of Palliative Care

Offprint requests to: Toshifumi KOSUGI, Saga-Ken Medical Centre Koseikan, Department of Palliative Care, 400 Kasemachi Nakabaru, Saga-shi, Saga 840-8571, Japan

*² Saga-Ken Medical Centre Koseikan, Department of Anesthesiology